Does the manufacturer offer OEM services?

Yes, the company provides both OEM and ODM services.

What are the lead times for orders?

The average lead time is one month for both peak and off-peak seasons.

Feed Additive Mycotoxin Binder Soluble Powder to Protect Animals

Name: Feed Additive Mycotoxin Binder Soluble Powder to Protect Animals
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1979273092

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$19.75-22.50

50 Bags

Sample price:US$2.00/kg.Request sample

Product profile

Customization

Available

Certification

QS, ISO

Shape

Powder

Model NO.

powder

Function

Toxin Binder

Type

Toxin Binder

Transport Package

25kg/Bag

Trademark

Moosun

Origin

China

HS Code

2309901000

Production Capacity

500tons/Month

Key features

High Efficacy Toxin Removal: Effectively removes more than 95% of mycotoxins in feed.

Dual Action Mechanism: Combines Glucose oxidase, modified montmorillonite, and mannan oligosaccharide.

Broad Application Scope: Suitable for all ages of poultry and livestock.

Enhanced Immunity Support: Releases immunosuppression and improves animal immunity.

Reduced Impurity Content: Modified montmorillonite reduces impurities by 90%.

Liver Protection: Cracks mycotoxins in the body and protects animal liver.

Long Shelf Life: Valid for 18 months when stored in a cool, dry, and dark place.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤8.71h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.